Jiangsu Hengrui Pharmaceuticals (01276): Injection SHR-9803 Obtained Drug Clinical Trial Approval Notice

Jiangsu Hengrui Pharmaceuticals (01276) announced that recently, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (hereinafter referred to as "the Company") has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration (NMPA) for the injection of SHR-9803 and will soon conduct clinical trials. The injection of SHR-9803 is a type 1 therapeutic biological product that can activate anti-tumor immune activity to treat tumors. It can specifically bind and eliminate regulatory T cells (Tregs) within tumors while reducing the impact on peripheral Tregs, avoiding excessive peripheral immune activation, and thus increasing safety and effectiveness. Currently, there are no similar drugs approved for marketing domestically or internationally. As of now, the cumulative research and development investment for the injection of SHR-9803 is approximately 18.3 million yuan (unaudited).